Department of Medical Oncology Practice, Schaffhausen, Switzerland
Research Article
Neoadjuvant Immunotherapy in Stage III Colon Cancer with Deficient Mismatch Repair: A Step Towards Mainstream Adoption? Single-center Experience
Author(s): Zuniga Ingrid, Peros Georgios, Fuchs Ivo, Schreiber Heide, Becker Bjoern, Boehm Steffen and Ortega Sanchez Guacimara*
Colon cancer remains a major cause of cancer-related mortality worldwide, with Locally Advanced Colon Cancer (LACC) accounting for a substantial proportion of newly diagnosed cases. Among these, tumors characterized by Deficient Mismatch Repair (DMMR) or High Microsatellite Instability (MSI-H) represent a distinct molecular subset, comprising approximately 10–15% of cases. While early-stage DMMR colon cancer is associated with a favorable prognosis, its resistance to conventional neoadjuvant chemotherapy has posed challenges in treatment optimization.. The emergence of immune checkpoint inhibitors has revolutionized the management of DMMR metastatic colorectal cancer, prompting investigations into their potential in earlier disease stages. Recent trials, including NICHE and NICHE-2, have demonstrated remarkable efficacy of neoadjuvant immunotherapy in DMMR colon cancer, reportin.. View More»
DOI:
10.35248/2471-8556.25.11(1).005